Navigation Links
Quorum Review IRB Executive Vice-Chair to Speak at DIA’s 49th Annual Meeting

Seattle, WA (PRWEB) June 13, 2013

Quorum Review IRB, the industry leader in central IRB services, announces its Executive Vice-Chair, Royce A. Morrison, MD, MS, as a presenter and panel chair at the Drug Information Association’s 49th Annual Meeting. This year DIA is held in Boston, MA, June 23-27, 2013.

Dr. Morrison chairs his first session “First-in-Human Studies: How Much Complexity Is Too Much?” on Tuesday, June 25 at 1:45 p.m. The meeting topic includes trends that disrupt standard early-phase sequences and drive study complexity, and the best practices to mitigate risks. Dr. Morrison focuses on “The IRB: Regulatory Protection” in his portion of the presentation. On Wednesday, June 26 at 10:15 a.m., Dr. Morrison chairs the session, “Pharmacometrics: Implications and Impact in Preclinical to Early Phase Clinical Development,” where panelists discuss the discipline of pharmacometrics in drug development and regulatory decision-making. Dr. Morrison will present “Opportunities to Take Advantage of Pharmacometrics” during that session. Later that afternoon at 4:00 p.m., he heads the panel discussion for “Pharmacometric Methods: Essential for Optimal Drug Development Strategy”. This session defines pharmacometrics and describes examples of its application across the range of drug and development and decision-making activities.

Dr. Morrison serves as Executive Vice-Chair on Quorum’s Review Board and is board certified in internal medicine as well as a Certified Physician Investigator by the Academy of Pharmaceutical Physicians and Investigators. He earned his MD degree at Stanford University and has practiced in both private and HMO settings, emphasizing geriatrics and HIV/AIDS. Dr. Morrison has been a member of the Board of Association of Clinical Pharmacology Units, and is Past President and Board member of the Northwest Association for Biomedical Research.

The DIA Annual Meeting is the largest multidisciplinary event that brings together a global network of professionals to foster innovation that will lead to the development of safe and effective medical products and therapies. More information about the 2013 conference is available on the DIA website.

For the latest on Quorum Review News and Events, visit

About Quorum Review IRB

Quorum Review is an independent review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing IRB review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human subject research protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.

Quorum’s best-in-class IRB services include 14 Board meetings each week plus expedited review, 24-hour site review turnaround, 36-hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s IRB service offerings include full study review in the US and Canada, a specialized Phase I team, and unique processes for post-approval and registry studies.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Quorum Review IRB Launches Site Enrollment Service
2. Quorum Review IRB Presents “IRB Review of Registries, Databases and Biobanking” at 2013 AAHRPP Conference
3. Quorum Review IRB to Present “eConsent and the iPad: a Case Study” at Global ACRP Conference
4. Quorum Review IRB Presents on Good Clinical Practice Essentials at MAGI’s 2013 Clinical Research Conference
5. Quorum Review’s CEO Presents on IRB Response to Key Changes in Clinical Research Practice
6. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
7. AADR comments on review that validates association between oral health and heart health
8. IUDs Work as Emergency Contraceptive: Review
9. ICU stays for worst asthma drop 74 percent, review finds
10. Antiretroviral treatment for preventing HIV infection: an evidence review for physicians
11. Announces The Top 3 Heart Rate Monitors
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
Breaking Medicine Technology: